Philip Morris (PM) Q2 2026: Op Margin 40.5%, EPS Down 8% Philip Morris International's second-quarter operating margin reached 40.5%, the highest in at least five quarters, as operating income rose 22.0% to $4,530 million on 10.4% revenue growth — yet diluted EPS fell 7.7% to $1.80. The entire gap sits below the operating line: a $511 million non-cash impairment of the company's Canadian equity investment, a $217 million year-over-year decline in quarterly equity-method income (to $159 million from $376 million; the six-month swing is a larger $825 million), and an effective tax rate that jumped roughly seven percentage points. Excluding the impairment alone, Q2 diluted EPS would have been approximately $2.13, up roughly 9% rather than down. For a defensive staples business whose equity story now rests on converting smokers to smoke-free products, the operating engine is running considerably better than the headline earnings line suggests.
- Condensed Consolidated Balance Sheet 1-1. Major Asset Items | Item | Dec 31, 2025 ($M) | Jun 30, 2026 ($M) | Change % | |------|-------------------|-------------------|----------| | Cash and cash equivalents | 4,872 | 5,999 | +23.1% | | Trade receivables | 4,572 | 5,179 | +13.3% | | Inventories | 11,478 | 11,436 | −0.4% | | Property, plant and equipment, net | 8,397 | 8,313 | −1.0% | | Goodwill | 17,264 | 16,917 | −2.0% | | Other intangible assets, net | 10,884 | 10,178 | −6.5% | | Equity investments | 2,891 | 2,130 | −26.3% | | Total assets | 69,185 | 68,271 | −1.3% | The single most informative line is equity investments, down $761 million. The condensed cash flow statement identifies $511 million of that as an impairment related to the RBH equity investment — Rothmans, Benson & Hedges, the Canadian subsidiary that has operated under Companies' Creditors Arrangement Act protection and is accounted for outside the consolidation. The contingencies note confirms that ten health care cost recovery cases and nine proposed class actions in Canada have been released under the CCAA plan of compromise. The filing does not state the cause of the impairment — Note 13 is not reproduced in the extracted text. The impairment is plausibly connected to this resolution, but the causal link is not established in the extracted filing text. Inventory composition tells a more encouraging story than the flat total. Finished product fell to $6,168 million from $6,830 million, a 9.7% drawdown, while leaf tobacco rose 8.8% to $2,639 million and other raw materials rose 18.3% to $2,629 million. Holding total inventory flat while revenue grew 10.4% is a working capital win, and the mix shift toward raw inputs suggests the finished-goods overhang carried into the year has been cleared rather than merely reclassified. Trade receivables grew 13.3% against 10.4% revenue growth — a modest divergence worth monitoring but not yet a signal. Note that $1,043 million of the balance is due from related parties, up from $839 million. Goodwill and intangibles declined without any impairment charge; the annual second-quarter review concluded no impairment was required, and management states each reporting unit's fair value was substantially in excess of carrying value. The declines are therefore currency translation and amortization, not write-downs. Management does flag the Wellness reporting unit as the one it continues to monitor. 1-2. Debt Structure — Financing vs. Operating Liabilities Financing debt totals $49,113 million (short-term borrowings $3,341 million, current portion of long-term debt $3,406 million, long-term debt $42,366 million), against $48,835 million at year-end. Gross debt is essentially unchanged, but net of the larger cash balance, net debt fell to $43,114 million from $43,963 million. The composition shift is the real story. Short-term borrowings ballooned from $168 million to $3,341 million while long-term debt fell $2,768 million. The financing section confirms the mechanism: $3,190 million of net short-term issuance funded against $2,543 million of net long-term repayment. Management has swapped term debt for short-dated paper. That lowers interest cost today — net interest expense fell to $470 million for the half from $541 million — but it converts a fixed obligation into one that must be rolled. Detailed maturity and coupon schedules sit in Note 11, which is not contained in the extracted filing text, so the rollover profile cannot be quantified here. Operating liabilities moved in the opposite direction: accounts payable fell to $3,919 million from $4,407 million, and taxes other than income taxes — predominantly excise — fell to $6,572 million from $7,555 million. Both are cash outflows that suppressed the half's operating cash generation. 1-3. Capital Structure PMI continues to report a total stockholders' deficit, at negative $6,657 million versus negative $8,028 million at year-end. This is structural rather than distress-related: cost of repurchased stock stands at $35,459 million against earnings reinvested in the business of $36,055 million, the accumulated legacy of buybacks and the 2008 Altria spin-off. Accumulated other comprehensive losses narrowed to $11,656 million from $12,296 million as currency translation reversed favorably. Notably, treasury stock decreased by $92 million and repurchased shares fell from 552,659,642 to 550,713,450. Shares were reissued for employee awards; none were bought back. Diluted share count rose slightly, from 1,558 million to 1,560 million. PMI is not currently repurchasing stock — dividends and deleveraging have full priority.
- Condensed Consolidated Statement of Earnings 2-1. Core Performance Metrics | Item | Q2 2025 ($M) | Q1 2026 ($M) | Q2 2026 ($M) | YoY | |------|--------------|--------------|--------------|-----| | Net revenues | 10,140 | 10,146 | 11,192 | +10.4% | | Gross profit | 6,866 | — | 7,659 | +11.5% | | Operating income | 3,712 | 3,893 | 4,530 | +22.0% | | Operating margin (%) | 36.6 | 38.4 | 40.5 | +3.9pp | | Net earnings attributable to PMI | 3,039 | 2,438 | 2,817 | −7.3% | | Diluted EPS ($) | 1.95 | 1.56 | 1.80 | −7.7% | For the six months, revenue rose 9.8% to $21,338 million, operating income rose 16.1% to $8,423 million, and net earnings attributable to PMI fell 8.3% to $5,255 million. Full-year 2025 operating margin was 36.6%, so the 40.5% posted in Q2 represents genuine expansion rather than seasonal noise. Operating leverage is running at roughly 2.1x — each 1% of revenue growth produced 2.1% of operating income growth. The prior-year base included a $41 million goodwill impairment on Swedish Match consumer accessories; normalizing for it, underlying operating income growth was approximately 20.7%, still comfortably above revenue growth. The bridge from operating income to net earnings is where the quarter turned. Working from the filing's figures: operating income of $4,530 million less $238 million net interest expense gives $4,292 million; adding $159 million of equity-method income and deducting the $511 million RBH impairment yields $3,940 million pre-tax; less $955 million of tax leaves $2,985 million of total net earnings. The prior-year quarter had $376 million of equity-method income and no impairment. Two drags compound. First, equity-method income for the half swung to negative $244 million from positive $581 million — an $825 million reversal, on top of the separate $511 million impairment. Second, the effective tax rate rose to 24.2% from 17.2%. Because the impairment attracted no tax benefit, part of that is arithmetic; excluding it, the rate was still 21.5%, roughly four points above prior year. The extracted filing text contains no management discussion of the tax rate driver, so the cause cannot be attributed here. 2-2. Segment Composition Effective January 1, 2026, PMI reorganized into three reportable segments — International Smoke-Free, International Combustibles, and the U.S. (which houses the Aspeya wellness unit). Prior-year figures were reclassified to conform, so the comparisons below are like-for-like. | Q2 2026 Segment | Revenue ($M) | YoY | Gross profit ($M) | YoY | GP margin | Prior GP margin | |-----------------|--------------|-----|-------------------|-----|-----------|-----------------| | International Smoke-Free | 3,877 | +14.2% | 2,716 | +17.1% | 70.1% | 68.3% | | International Combustibles | 6,459 | +9.8% | 4,388 | +11.5% | 67.9% | 66.9% | | U.S. | 856 | −0.7% | 555 | −9.2% | 64.8% | 70.9% | | Total | 11,192 | +10.4% | 7,659 | +11.5% | 68.4% | 67.7% | International Smoke-Free is doing the work — fastest growth, highest margin, and the only segment expanding margin by nearly two points. International Combustibles, the segment a conversion narrative implies should be in managed decline, grew revenue 9.8% and expanded gross margin to 67.9%. Pricing power in cigarettes remains intact and is quietly funding the transition. The U.S. is the problem. Revenue slipped 0.7% while gross profit fell 9.2%, compressing segment gross margin by 6.1 points. Product-category disclosure sharpens the picture: U.S. smoke-free revenue was $768 million in Q2 versus $766 million, essentially flat, but $1,311 million for the half versus $1,584 million — down 17.2%. The deterioration was concentrated in the first quarter and has since stabilized on the revenue line, though not on margin. Note that segment gross profit excludes marketing, administration and research costs, which are not allocated to segments, along with net interest expense and corporate expenses — so these margins are not comparable to peers' reported gross margins without adjusting for differing cost-allocation conventions.
- Condensed Consolidated Statement of Cash Flows | Item (six months) | H1 2025 ($M) | H1 2026 ($M) | Change | |-------------------|--------------|--------------|--------| | Operating cash flow | 3,062 | 5,093 | +66.3% | | Investing cash flow | (2,750) | 23 | +2,773 | | Financing cash flow | (890) | (3,879) | −2,989 | | Capital expenditures | (760) | (733) | −3.6% | | Free cash flow | 2,302 | 4,360 | +89.4% | | Ending cash (incl. restricted) | 4,176 | 6,024 | +44.3% | Operating cash flow rose $2,031 million even as net earnings fell $418 million — a combination that demands scrutiny rather than applause. The reconciliation shows roughly $1,608 million came from a smaller working capital drag: accrued liabilities and other current assets consumed $1,081 million versus $1,972 million, income taxes $200 million versus $611 million, and inventories $80 million versus $419 million. A further $511 million is the non-cash impairment added back. Only a modest remainder reflects improved underlying conversion. Earnings quality accordingly improved but has not been fixed. Operating cash flow to net earnings was 0.91x, up sharply from 0.51x — still below 1.0x. Adjusting both sides to remove the impairment gives roughly 0.75x. PMI's cash generation is seasonally weighted to the second half, so a first-half ratio under 1.0x is not itself alarming, but the improvement is substantially a working capital timing effect rather than a step-change in cash conversion. Investing cash flow swung positive almost entirely on derivative collateral: $543 million received versus $1,953 million posted a year earlier, a $2,496 million swing driven by currency movements against the company's net investment hedges. This is a treasury flow, not an operating improvement. Capital expenditure of $733 million equals just 3.4% of revenue — an asset-light profile appropriate to a business whose growth is now driven by consumable refills rather than new capacity. Financing outflows widened to $3,879 million as dividends paid rose to $4,604 million from $4,222 million. Dividends consumed 105.6% of first-half free cash flow, down markedly from 183.4% a year ago. Given second-half seasonality this is manageable, but it confirms the dividend is currently absorbing more than the entirety of first-half free cash flow — PMI's capital allocation leaves no room for balance-sheet deleveraging until the second-half earnings wave materializes.
Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. LineVest News is an independent publication and is not affiliated with any brokerage or financial advisory firm. All data sourced from Philip Morris International's SEC Form 10-Q filing for the quarter ended June 30, 2026. Past performance is not indicative of future results.
